Isolation and Quantification of Blood Apoptotic Bodies, a Non-invasive Tool to Evaluate Apoptosis in Patients with Ischemic Stroke and Neurodegenerative Diseases

Table 3 Yield of the procedure for apoptotic body isolation

Subjects enrolled	Total n° ApB/50 μl plasma	n° isolated ApB/50 μl plasma	ApB recovery
C	113,536	48,480	42.7%
IS1	171,554	125,235	73%
IS2	93,750	75,000	80%
IS3	148,552	112,900	76%
IS4	202,602	160,056	79%
MS1	948,015	729,972	77%
MS2	77,723	65,288	84%
MS3	712,342	555,627	78%
MS4	164,020	123,015	75%
PD1	413,381	326,571	79%
PD2	261,188	211,563	81%
PD3	399,890	295,919	74%
PD4	631,363	517,718	82%
H1	52,565	42,578	81%
H2	37,753	29,070	77%
H3	45,243	39,362	87%
H4	53,474	39,571	74%
H5	20,720	16,576	80%
H6	35,075	26,657	76%

The study included the isolation of plasma apoptotic bodies, by the described protocol, from patients with ischemic stroke (IS), multiple sclerosis (MS), Parkinson’s disease (PD) and from control subjects (Healthy:H). As a control (C), plasma apoptotic bodies purification from an ischemic patient was performed following the traditional approach
Results representing flow cytometry analysis are expressed as mean of duplicates

ISSN: 1480-9222